BUSULFANUM
Alpha-Mannosidosis
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Alpha-Mannosidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Cyclosporin A Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Equine Atg Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Cald Hr-D Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Thiotepa University of Florida | Phase 1/2 | CCC |
Campath-1H Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Duoc-01 Joanne Kurtzberg, MD | Phase 1 | CC |
Same molecule, other indications
BUSULFANUM is also rated in:
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →